Finance Watch: Have Investors Reached IPO Fatigue?

Only Two Of Six Newly Public Companies Trade Above IPO Price

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.

Finance Watch

Initial public offerings in the US have been remarkable in 2020 with 70 biopharmaceutical company IPOs so far this year compared with the full-year 2019 total of 50 first-time offerings. However, while the average return for drug developers that went public during the first three quarters of this year generated an average return well into the double digits, only two out of six firms that went public since 13 October have generated a positive return for IPO investors.

It remains to be seen whether this recent micro trend in biopharma IPO performance is a sign that investors are...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.